CRISPR and Genome Editing – Products

But how do you purify small volumes for preclinical and clinical studies without losing too much to processing or leaving capacity unused?

This app note highlights a uniquely protective environment to support cell viability and integrity during incubation and shield cells against shear stress during subsequent analysis.

Rapid, sensitive, and validated detection of viral replication genes using droplet digital™ PCR during cell and gene therapy production.

N4 Pharma PLC (AIM: N4P), recently acquired a controlling interest in Nanogenics Limited.

New off-the-shelf system reduces the cost and risk of lentiviral (LV) production for cell and gene therapy developers. Single-plasmid transfection minimizes GMP plasmid costs and supply chain risk.

Integrating our GMP proteins into your manufacturing process has never been easier. With our affordable GMP growth factors, maintain that flexibility to either directly use GMP grade or slowly transition with our 'pre-GMP' premium grade proteins.

Manufacturing cell therapies and other innovative medicines can be a challenge. Our tools and solutions are designed to work with you from the first step. Want to learn more? Explore our webpage and brochure and find what’s right for you!

License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness.

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced its second Japanese Patent.

Enter the era of CRISPR/Cas9 – a game-changer in unraveling life's intricacies. Unleash the potential to manipulate genes, a breakthrough cornerstone in biomedicine and drug discovery.